



(51) International Patent Classification:

A61K 31/192 (2006.01) *C07C 271/28* (2006.01)
A61K 31/27 (2006.01) *C07D 213/75* (2006.01)
A61K 31/381 (2006.01) *C07D 217/16* (2006.01)
A61K 31/415 (2006.01) *C07D 231/36* (2006.01)
A61K 31/421 (2006.01) *C07D 263/48* (2006.01)
A61K 31/44 (2006.01) *C07D 333/16* (2006.01)
A61K 31/47 (2006.01) *A61P 19/04* (2006.01)
C07C 53/134 (2006.01)

(21) International Application Number:

PCT/US2011/063465

(22) International Filing Date:

6 December 2011 (06.12.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/420,716 7 December 2010 (07.12.2010) US

(71) Applicant (for all designated States except US): **AMIRA PHARMACEUTICALS, INC.** [US/US]; Route 206 & Province Line Road, Princeton, New Jersey 08543-4000 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SEIDERS, Thomas, Jon** [US/US]; c/o Amira Pharmaceuticals, Inc., 9535 Waples Street, Suite 100, San Diego, California 92121 (US). **WANG, Bowei** [US/US]; 10 Kirkview Circle, Westfield, New Jersey 07090 (US). **HUTCHINSON, John, Howard** [US/US]; 3435 Richmond Street, San Diego, California 92103 (US). **STOCK, Nicholas, Simon** [GB/US]; 7087 Camino Degrazia #150, San Diego, California 92111 (US). **VOLKOTS, Deborah** [US/US]; 2004 University Ave Apt 206, Berkeley, CA 94704 (US).

(74) Agents: **GIBBONS, Maureen, S.** et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(54) Title: LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND USES THEREOF

(57) Abstract: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

